IMS Health Expands Oncology Analyzer in China

Pharma market research giant IMS Health has expanded its IMS Oncology Analyzer market measurement tool to provide anonymized patient-level information across several additional cities in China.

IMS Health was recently acquired by investment firms TPG Capital and the Canada Pension Plan Investment Board (CPPIB), for $5.2bn.

Its IMS Oncology Analyzer is an evidence-based, quant market research tool used to measure life cycle management strategies, product performance plans, new indication opportunities and many other commercial planning activities.

The tool now covers twelve cities in China, where it provides insights in areas such as product adoption, dosing and market sizing.

'The focus on cancer prevention and treatment is leading to greater access to all cancer therapies in China, as well as improved diagnoses and treatments for an aging patient population,' explains Steven Gavel, Global Director of Oncology. 'IMS Oncology Analyzer is an essential tool for measuring success in this rapidly expanding market.'

According to the firm, by the end of 2011 China is expected to become the world's third-largest pharmaceutical market, growing more than 20% annually.

The Analyzer is already available in the UK, France, Italy, Spain, Germany, Turkey, the Netherlands, Japan, Korea and Taiwan.

Earlier in the month, the company promoted Sati Sian to the post of General Manager of its China operations, after two decades with the firm. He was previously General Manager of the company's Commercial Effectiveness business.

Web site: www.imshealth.com .